# Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)

> **NCT06087276** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Praxis Precision Medicines** · enrollment: 1000 (estimated)

## Conditions studied

- Essential Tremor

## Interventions

- **DRUG:** 60 mg ulixacaltamide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06087276
- **Lead sponsor:** Praxis Precision Medicines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-11-02
- **Primary completion:** 2025-09
- **Final completion:** 2026-12
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06087276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06087276, "Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06087276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*